Merck & Company Inc (MRK)vsRapport Therapeutics, Inc. Common Stock (RAPP)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
RAPP
Rapport Therapeutics, Inc. Common Stock
$43.62
+0.37%
HEALTHCARE · Cap: $2.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 332745% more annual revenue ($66.57B vs $20.00M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
RAPP
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for RAPP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RAPP
The strongest argument for RAPP centers on Debt/Equity, Altman Z-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RAPP
The primary concerns for RAPP are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RAPP carries more volatility with a beta of 1.03 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rapport Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases, especially Alzheimer's and associated cognitive disorders. Utilizing proprietary drug candidates and cutting-edge technology platforms, the firm is focused on meeting significant unmet medical needs through comprehensive scientific research and clinical trials. With a robust pipeline of innovative treatment options, Rapport Therapeutics is strategically poised to reshape the treatment paradigm for individuals facing the challenges of cognitive impairments, enhancing patient quality of life and contributing to the broader healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?